Grifols’ Biotest to launch Yimmugo in USA

Spanish plasma-based medicines producer Grifols (MCE: GRF) announced that Yimmugo, an innovative intravenous immunoglobulin (IVIg) therapeutic, produced by Biotest – a Grifols group company – will officially launch in the USA for the treatment of primary immunodeficiencies (PID).

Following Food and Drug Administration (FDA) approval for US commercialization earlier in 2024, the first for a Biotest medicine, Yimmugo will now be available to help address the growing number of patients living with primary immunodeficiencies and other medical conditions in the country. It is estimated that one in every 1,200 people in the USA is affected by PID, a condition where the body’s immune system’s ability to fight infections and diseases is weakened or does not function properly.

Developed by Biotest, Yimmugo is manufactured using a state-of-the-art process at the company’s FDA-certified “Next Level” production facility in Dreieich, Germany.